Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group
by
Cunningham LA
Vine Street Clinical Research Center,
Springfield, Illinois 62701, USA.
Ann Clin Psychiatry 1997 Sep; 9(3):157-64

ABSTRACT

This was a randomized, double-blind, placebo-controlled comparison of the efficacy and safety of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR). Outpatients with DSM-III-R major depression were randomly assigned to venlafaxine XR, 75 mg once daily, venlafaxine IR, 37.5 mg twice daily, or placebo for a maximum of 12 weeks. If the response was inadequate after 2 weeks of treatment, the dosage of venlafaxine XR or IR could be increased to 150 mg daily. The primary efficacy variables were the 21-item Hamilton Depression (HAM-D) Rating Scale total score and depressed mood item, the Montgomery-Asberg Rating Scale (MADRS) total scores, and the Clinical Global Impressions (CGI) severity scale. Two hundred seventy-eight patients were evaluated for efficacy. Venlafaxine XR was significantly superior (p < 0.05) to placebo beginning at week 2 for the HAM-D, week 3 for the MADRS, and week 4 for the CGI severity. Similarly, venlafaxine IR was significantly superior (p < 0.05) to placebo beginning at week 2 on the HAM-D total and depressed mood item, week 3 on the MADRS total, and week 6 on the CGI severity scales. Venlafaxine XR exhibited superiority (p < 0.05) over venlafaxine IR at week 12 for all efficacy variables. The most common treatment-emergent adverse event with venlafaxine XR was nausea. The incidence of nausea was highest during the first 2 weeks with a low likelihood of developing nausea thereafter. The results of this study indicate that venlafaxine XR is safe, effective, and well tolerated for the treatment of major depression at once-daily doses ranging from 75 to 150 mg.

SSRIs
NARIs
Serotonin
Tramadol
Noradrenaline
Venlafaxine for GAD
Venlafaxine v fluoxetine
Venlafaxine pharmacology
Venlafaxine for dysthymia
Venlafaxine for depression
Venlafaxine plus bupropion
Venlafaxine: pharmacokinetics etc
Venlafaxine SR and major depression
Venlafaxine (Effexor) v clomipramine for OCD
Venlafaxine plus diphenhydramine (Benadryl)
Venlafaxine, emotional processing and the brain
Depression treated with different formulations of venlafaxine
February 2008: FDA licenses antidepressant desvenlafaxine (Pristiq)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family